LARS anticorps (C-Term)
Aperçu rapide pour LARS anticorps (C-Term) (ABIN359572)
Antigène
Voir toutes LARS AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- This antibody reacts to LARS.
-
Purification
- Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS
-
Immunogène
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human LARS.
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
-
ELISA: 1/1,000. Western blotting: 1/50 - 1/100. Immunohistochemsitry: 1/10 - 1/50.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- LARS (Leucyl-tRNA Synthetase (LARS))
-
Autre désignation
- LARS
-
Sujet
- LARS, a cytosolic leucine-tRNA synthetase, a member of the class I aminoacyl-tRNA synthetase family. This enzyme catalyzes the ATP-dependent ligation of L-leucine to tRNA(Leu). It is found in the cytoplasm as part of a multisynthetase complex and interacts with the arginine tRNA synthetase through its C-terminal domain.Synonyms: EC=6.1.1.4, KIAA1352, LARS, LeuRS, Leucine-tRNA ligase, Leucyl-tRNA synthetase, cytoplasmic
-
ID gène
- 51520, 9606
-
UniProt
- Q9P2J5
-
Pathways
- EGFR Signaling Pathway
Antigène
-